The Life Raft Group is pleased to announce the release of the ninth issue of The GIST Cancer Journal, the official journal of the Life Raft Group. The journal is intended to serve as a comprehensive and authoritative resource of scientifically valid information for physicians and allied health care professionals regarding advances in the diagnosis […]
Dr. Jonathan Trent, Dr. Wilbur B. Bowne, ESMO, GIST, GIST Cancer Journal, neo-adjuvant, protein kinases, Sarcoma
The Life Raft Group is pleased to announce the release of the eighth issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely to GIST. The journal is intended to serve as a comprehensive and authoritative resource of scientifically valid information for physicians and […]
CTOS, D842V mutation, GIST Cancer Journal, Immunotherapy, PDGFRA, Sarcomas Research
Blueprint Medicines presented new preclinical data on its drug candidate, BLU-285, and its potential value in treatment-resistant GIST and on novel cancer drug targets at the AACR (American Association for Cancer Research) Annual Meeting in Philadelphia this past week. BLU-285 is a targeted therapy that acts as a potent inhibitor of PDGFRa D842V and KIT […]
AACR, Blueprint Medicines, D842V, GIST research, gist treatment
A new study published by Clinical Cancer Research found that crenolanib is a potent inhibitor of imatinib resistant PDGFRA kinases associated with Gastrointestinal Stromal Tumor, including the PDGFRA D842V mutation found in about 5 percent of GISTS. Crenolanib is an investigational new drug being developed by AROG Pharmaceuticals. Crenolanib is a tyrosine kinase inhibitor that […]
D842V mutation, GIST, GIST News, PDGFRA, Stromal Tumor